Chapter 15. Targeting Measles Virus Entry
- David T. Curiel M.D. and
- Joanne T. Douglas Ph.D.
Published Online: 31 MAR 2003
Copyright © 2002 John Wiley & Sons, Inc.
Vector Targeting for Therapeutic Gene Delivery
How to Cite
Hammond, A. L., Plemper, R. K. and Cattaneo, R. (2003) Targeting Measles Virus Entry, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch15
Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA
- Published Online: 31 MAR 2003
- Published Print: 9 AUG 2002
Print ISBN: 9780471434795
Online ISBN: 9780471234302
- measles virus;
- oncolytic therapy;
- cell attachment;
- cell entry;
- domain display;
- single chain antibodies
Measles virus (MV) replicates preferentially in transformed cells. Its negative strand RNA genome does not integrate or recombine, and its pleomorphic envelope does not impose a rigid upper limit to the size of packaged genomes. To redirect cell entry, replicating MVs have been produced in which the standard attachment protein was replaced by one with an additional specificity domain. Specificity domains as diverse as a growth factor or a single chain antibody are able to confer entry through targeted receptors. MV mutants with reduced or ablated binding to the natural receptors are being produced, and may have applications in different oncolytic therapies.